Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

New Curcumin Extract Found to Counteract Inflammation at the Genetic Level

New research has found a trace component of the standard curcumin extract, bisdemethoxycurcumin (BDMC), may be up to 7X more potent on a key anti-inflammatory target than the curcumin extract itself.


New biomedical research released today jointly by The Rhema Group and Biologic Pharmamedical, has shown that a trace component of the standard curcumin extract, bisdemethoxycurcumin (BDMC), is proven to be up to 7X more potent on a key anti-inflammatory target than the curcumin extract itself. This discovery is significant because it means curcumin pharmacology can now be more precisely targeted for therapeutic results.  

This patent-pending research discovery was made by The Rhema Group’s Chief Science Officer, Franco Cavaleri, BSc, PhDc, who is also the principal research scientist at Biologic Pharmamedical. Cavaleri is currently completing a doctoral degree in Experimental Medicine at UBC’s Faculty of Medicine, Center for Brain Health. Cavaleri’s research has proven for the first time how the modified curcumin extract targets and neutralizes a key protein central in the regulation of inflammation, while significantly enhancing the efficacy of the anti-inflammatory properties of curcumin.   

"Inflammation is central to every disease pathology at one level or another. This new pointed pharmacological research on curcumin reveals that although BDMC exists in extremely low concentrations in standardized curcumin extracts -between 0.5 to 1.5 per cent - it can play a key role in therapy if it is raised to 30 per cent. This enhancement fortifies the mechanism by which curcumin can inhibit nuclear, MSK1, a facilitative kinase protein central to the inflammatory process,” says Cavaleri.   MSK1 has been recently shown to be dysregulated in diseases like drug resistant cancers and chronic or drug resistant autoimmune disease.

This new understanding reveals how curcumin pharmacology can be designed to be more selective in targeting specific genomic activity. Elevated levels of BDMC to 30 per cent is showing dramatic results in the enhancing the efficacy of curcumin’s anti-inflammatory properties.

The Rhema Group, a leading nutraceutical formulator and manufacturer to global markets, has partnered with Biologic Pharmamedical Research, a private biomedical research organization,  to bring-to-market patent-protected formulations with BDMC levels elevated to 30 per cent under the trade name Curcumin BDM30™.  Both companies are working together to use Cavaleri’s patent-pending research to develop new evidence-based curcumin-drug and supplement designs for the functional food and nutraceutical industries. This inflection is expected to change how curcumin is prescribed in the future to help improve lives.

Cavaleri will be at SupplySide West 2016 in Las Vegas on October 6 and 7, and will be giving informal presentations on his patented research on Curcumin BDM30™, and how companies can use this new ingredient in formulations.  Visit The Rhema Group at SupplySide booth # K111. 

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.